精神分裂症治療藥市場：新藥與新市場領導者的可能性

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Schizophrenia is a complex disease whose biology is not completely understood, a reality that presents a major hurdle to companies developing new therapies for schizophrenia. As a result, many companies have focused on the development of agents that, like existing agents, target the serotonin and dopamine receptors. Thus, over the next several years, emerging treatments for schizophrenia are expected to function by the same general mechanisms as existing therapies. How can they distinguish themselves and gain market share? What strategies will companies working in this field employ to extend the use and sales of their agents? What are the prospects for development of agents that work via novel mechanisms? In this report, we provide an overview of the disease of schizophrenia and discuss currently available drugs and emerging therapies in late-stage development. Last, we assess the current competition as well as market prospects and competitive strategies for these agents.

Table of Contents

Introduction

Overview of Schizophrenia

• Disease Symptoms, Onset, and Prevalence
• Pathophysiology and Risk Factors for Schizophrenia

Current Therapies for Schizophrenia

• Typical Antipsychotics
• Atypical Antipsychotics
• A Side-by-Side Comparison: Results from the Clinical Antipsychotic Trials of Intervention
• Effectiveness (CATIE)

Emerging Therapies for Schizophrenia

• Serotonin and Dopamine Receptor Antagonists
  • H. Lundbeck's Serdolect
  • Dainippon Sumitomo Pharmaceuticals' Blonanserin
  • Johnson & Johnson's Paliperidone
  • Organon/Pfizer's Asenapine
  • Vanda Pharmaceuticals' Iloperidone
• Dopamine Partial Agonists
• Serotonin Inverse Agonists
• Novel Agents
  • Neurokinin Receptor Antagonists
  • AMPA Receptor Modulators
  • Secretin Antagonists

Current Market and Future Prospects for Schizophrenia Therapies

相關商品

精神病相關市場調查報告書

抗精神病藥物市場(∼2017年):金普薩(Zyprexa)·安立復(Abilify)·思樂康(Seroquel)·哲思(Geodon)專利到期，及學名藥開始販售將限制開發平台分子商業機會的可能性
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules
價格 : US $ 3500
出版日期 : 2012年01月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年01月

憂鬱症:針對二線患者的新一代產品競爭
Product Profiles: Depression - Next generation vies for second-line patients
價格 : US $ 11400
出版日期 : 2011年11月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!